Replies to post #306471 on NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Why would that be tough to hear? Virtually every point has been widely presented and discussed in Linda Liau’s and Dr. Prin’s lectures and on almost every point, there are substantial reasons to be quite optimistic given actual results and ongoing research and planned trials.

Try to understand what a “cold tumor” is and why PDL1 blockers would not make a tumor “hot”, and also why a vaccine in combination with a PDL1 blocker later in the lecture would be so helpful, as well as why contrary to his point about GBM having so few targets, most immune therapies for GBM in the past have only targets single or just a few targets, allowing the tumors to evolve away and why having a therapy that targets all of the patient‘s specific antigens is superior.

That is a very general and not specific to DCVax-L presentation. You’ll need to do some more homework. Don’t invest until you do it though. Never invest in anything you don’t understand and I’m which you are not confident. You’ll need to convince yourself that it’s worth the risk.

[Horseb4CarT]

As you pointed out this was 2 years ago and it sounded to me that he referred to CarT around the time he was mentioning low percentage response. Multiple attempts/trials have failed so dcvax-l has had to deal with the challenges this doctor enumerated and to be successful I think dcvax has to have done enough better across multiple dimensions, or put more simply the secret sauce of process and techniques combine well enough to achieve improvement over SOC and other failed vaccines.

I’m not a medical doctor nor researcher in this field so this is just imho.